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Distinct temporal trends in breast cancer incidence from 1997
to 2016 by molecular subtypes: a population-based study of
Scottish cancer registry data
Ines Mesa-Eguiagaray1, Sarah H. Wild1, Philip S. Rosenberg2, Sheila M. Bird1,3, David H. Brewster1, Peter S. Hall 1,4, David A. Cameron4,
David Morrison5 and Jonine D. Figueroa1,4
BACKGROUND: We describe temporal trends in breast cancer incidence by molecular subtypes in Scotland because public health
prevention programmes, diagnostic and therapeutic services are shaped by differences in tumour biology.
METHODS: Population-based cancer registry data on 72,217 women diagnosed with incident primary breast cancer from 1997 to
2016 were analysed. Age-standardised rates (ASR) and age-specific incidence were estimated by tumour subtype after imputing the
8% of missing oestrogen receptor (ER) status. Joinpoint regression and age–period–cohort models were used to assess whether
significant differences were observed in incidence trends by ER status.
RESULTS: Overall, ER-positive tumour incidence increased by 0.4%/year (95% confidence interval (CI): −0.1, 1.0). Among routinely
screened women aged 50–69 years, we observed an increase in ASR from 1997 to 2011 (1.6%/year, 95% CI: 1.2–2.1). ER-negative
tumour incidence decreased among all ages by 2.5%/year (95% CI: −3.9 to −1.1%) over the study period. Compared with the
1941–1959 birth cohort, women born in 1912–1940 had lower incidence rate ratios (IRR) for ER+ tumours and women born in
1960–1986 had lower IRR for ER− tumours.
CONCLUSIONS: Future incidence and survival reporting should be monitored by molecular subtypes to inform clinical planning
and cancer control programmes.
British Journal of Cancer https://doi.org/10.1038/s41416-020-0938-z
BACKGROUND
Breast cancer incidence is rising and it is the most common cancer
among women worldwide.1 Breast cancer is not a single disease,
but comprises multiple subtypes, with oestrogen receptor (ER)
expression, a key marker of prognostic and aetiologic signifi-
cance.2 ER+ tumours, which are amenable to targeted anti-
oestrogenic therapies, such as tamoxifen and aromatase inhibi-
tors, are the most common type of breast cancers accounting for
65–75% of breast cancer cases in high-income populations.3
Progesterone receptor (PR) is also a commonly tested marker of
hormone responsiveness that is highly correlated with ER. Tumour
overexpression of the human epidermal growth factor receptor 2
(HER2) was identified over two decades ago. The discovery of
HER2 laid the foundation for biological therapies, which were
shown to be clinically effective in treating tumours expressing this
marker. HER2-targeted therapies have been widely available in the
United Kingdom since 2006.4 ER− tumours are rarer, have an
earlier age of onset and worse prognosis than ER+ tumours, in
part because fewer targeted treatments are available than for ER+
tumours. In addition to prognostic differences, epidemiologic
studies have shown aetiologic differences by tumour subtypes.5,6
There are relatively few population cancer registries that collect
ER, PR and HER2 data, the key distinguishing markers for
molecular subtypes of breast cancer. Recent analyses support
divergent incidence trends by ER status in the United States,
Denmark and Ireland, with ER+ breast cancer incidence increasing
and ER− breast cancer incidence decreasing.7–9 Data on a
combination of subtypes using ER, PR and HER2 are even more
limited, with few reports from the United Kingdom.10–12 ER, PR
and HER2 molecular markers are used often as surrogates for the
intrinsic subtypes of breast cancer defined by mRNA expression
profiling13 because, unlike genetic profiling subtypes, the
molecular markers have been measured routinely in recent years.
In the age of precision medicine, quantifying and monitoring
cancer incidence by molecular subtypes are important in
optimising public health prevention programmes, the allocation
of resources and availability of screening, diagnostic and
therapeutic services and for improving outcomes.14 An important
issue in assessing trends by ER status is the need to account for
missing data, as completeness of marker data has improved over
time, but imputation methods can be applied to address this
limitation.7–9,15
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Within Scotland’s renowned, high-quality routine electronic
health records, the Scottish cancer registry is an excellent resource
to investigate temporal trends in cancer incidence. Data collection
began for ER in 1997 and PR and HER2 in 2009, and so provides
data almost a decade earlier than other UK national registries.
While monitoring of breast cancer incidence in the United
Kingdom is standard,16,17 these data have not been presented
by molecular subtypes, despite substantial evidence that hetero-
geneity exists by ER status.6,18–20
Here we report on breast cancer incidence trends in Scotland by
ER and ER/HER2 combinations using several statistical methods:
(1) age-standardised and age-specific incidence rates, which are
typically used to report cancer statistics,21 (2) joinpoint regression
models to determine whether significant changes occurred during
1997–2016, and the speed at which they have occurred22 and (3)
age–period–cohort (APC) models23–25 based on generalised linear
model theory to enable description of age, period and birth cohort
effects to provide possible clues to potential underlying factors
contributing to incidence trends, and thereby inform public health
and NHS programmes.
METHODS
Data and cohort definition
All primary invasive breast cancers (defined on the basis of the
International Classification of Diseases, 10th revision code of
C50) diagnosed in women aged 20+ years, between 1997 and
2016, were ascertained from the Scottish cancer registry held by
Information Services Division (ISD) of NHS National Services
Scotland. The Scottish cancer registry achieves 98% breast
cancer case ascertainment and is over 99% complete.26 Breast
cancer incidence after a previous cancer is considered a
different aetiology (i.e. possible different risk factors such as
radiation exposure amongst others) and, while an interesting
topic, was not the major interest of this analysis. Supplementary
Fig. 1 describes how the final study population was derived:
notably, by exclusion of men and women who had a prior non-
breast primary tumour. ER status was based on Allred scoring.27
Women with primary breast cancer are the basis for analysis,
each characterised by her worst-prognosis tumour. In our study
population, 3653 women (5% of the study population) had
multiple invasive breast cancers denoted in the cancer registry.
The first primary invasive breast cancer was chosen if the time
between diagnoses was >6 months, whereas for those with
more than 1 diagnosis <6 months apart (n= 2094), the more
advanced invasive cancer was selected. Of those 2094, 1837
(88%) had the same ER status, 154 (0.07%) had different ER
status and the rest had one or more of the records with missing
ER status. We therefore prioritised the record with less missing
data. Given that only 0.07% cases lacked agreement in ER status,
this prioritisation had negligible impact on the results; using
tumours (not individuals) as the numerator, which is typically
done in regular cancer reporting, overestimates the incidence
rates of breast cancer, and we used one tumour per person to
minimise bias in time trends. Permission for use of the data was
obtained from the Public Benefit and Privacy Panel (PBPP) of
NHS Scotland (reference number 1718-0057), and analyses were
conducted in the Scottish National Safe Haven.28
Additional demographic and tumour data obtained were age at
diagnosis, NHS Scotland regions (North, South East and West),
tumour grade (grade I—well differentiated to III—poorly differ-
entiated), tumour size (less than 10mm, 10–20mm and more than
20mm), nodal involvement (yes or no), screen-detected tumour
(yes or no) and the status of molecular markers ER, PR and HER2
(positive, negative or unknown). ER and PR status are measured
using immunohistochemistry (IHC), and HER2 status was assessed
using a combination of IHC with fluorescent in situ hybridisation
for equivocal (2+) cases. Previous studies have noted that
assessment of ER status reliability is high with an error rate below
5%.29 ER/HER2 combinations were used as surrogates for the four
intrinsic subtypes of breast cancer, the gold standard for which
uses mRNA expression profiling. ER+/HER2− was used as a
surrogate for Luminal A tumours, ER+/HER2+ for Luminal B,
ER−/HER2+ for HER2-enriched tumours and ER−HER2− for triple-
negative tumours. The high quality of these data has been
previously described.30
Statistical methods
Missing ER and ER/HER2 status were imputed conditioned on age
and year of diagnosis, with the assumption that data were missing
at random, using a validated method.7–9 Age-standardised
incidence rates (ASR) per 100,000 women were calculated using
the direct method, the European standard population (2013) and
mid-year estimates of the Scottish population for each age and
year.31 Age-specific incidence rates were calculated for 5-year age
groups (20–24 to 90+) and individual calendar years using two
approaches: with the number of tumours as the numerator for
consistency with routine reporting, and with one tumour per
woman as the numerator for all other analyses. ASRs were
calculated for all age groups combined and for three separate age
groups, with the middle group defined on the basis of eligibility
for routine breast screening in Scotland (20–49 years, 50–69 years
and 70 years or older), and for each ER status and ER/HER2
combinations.
Joinpoint regression models were used to describe breast
cancer incidence rates overall, by ER status and ER/HER2
combinations for all women in the cohort and for three age
groups (20–49, 50–69 and 70+ years). Joinpoint models describe if
changes in incidence trends occur and identify the time points at
which a change is observed (referred to as joinpoints). The
permutation test method, as described by Kim et al.,22 was used
iteratively: it starts by testing the null hypothesis of a simple
model with zero joinpoints against the alternative hypothesis of a
more complex model with the maximum number of joinpoints
previously specified (3 joinpoints for this study). The procedure
continues until all possible numbers of joinpoints have been
tested. A total of 4,499 permutations are performed, and the p-
value test is adjusted for multiple testing using the Bonferroni
correction.32 In the final model, the estimated annual percentage
change (EAPC) for each of the periods identified is calculated. The
average annual percent change (AAPC) is also reported as a
measure of the overall trend from 1997 to 2016. Joinpoint
regression software is a free open- access software that can be
downloaded at https://surveillance.cancer.gov/joinpoint/.33
APC models were fitted for age-standardised incidence of ER+
and ER− tumours. The APC model provides a unique set of best-
fitting log10 incidence rates obtained by maximum likelihood
estimators for period, age and cohort, which have been shown to
provide similar rates to ASR, but allow investigation of differences
by birth cohorts—with the middle cohort as referent—which are
not investigated in ASR or joinpoint regression analysis. As a
consequence of small numbers in some strata, we restricted these
models to women aged 30–85 years and used 28 2-year age
groups (from 30–31 to 84–85) and 10 2-year periods (from
1997–1998 to 2015–2016) of calendar year of diagnosis, which
covered birth cohorts from 1912 to 1986. The net drift, similar to
the EAPC and AAPC estimates, is reported with 95% confidence
intervals (CI). Local drifts were also estimated and describe the
annual percentage change for each age-specific rate over time.34
In addition, period and cohort rate ratios are also presented to
compare the age-specific rates in each period or cohort with the
reference points in the middle of the study period and birth
cohort (2006 for period and 1949 for cohort). Together with cohort
rate ratios (CRR), a combination test of significance for the
complete cohort deviations is reported. This new combination test
aims to determine if there is an association of the observed rates
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with the birth cohorts above the linear influences represented by
the net drift. The test provides a more robust method than the
traditional Wald test while correcting for multiple testing. With the
exception of joinpoint regression, all analyses were carried out
using R.35
RESULTS
Characteristics of the cohort by ER status
Between 1997 and 2016, 72,217 women of 20 years of age or older
were diagnosed with at least one invasive breast cancer in
Scotland (Table 1). Seventy-six percent of these tumours were
ER+, 16% were ER− and 8% had unknown ER status. However, the
percentage of missing ER status decreased over time from 20% in
1997 to 2% in 2016. Proportions with unknown ER status differed
by region and age: higher in the West compared with the North
and Southeast of Scotland and in women aged 70 years or older
compared with women younger than 70 years (14% missing vs.
5%). Almost half of breast cancers were diagnosed among women
of 50–69 years of age, similar to the range for eligibility for routine
breast cancer screening (50–70 years) since 2003.
Tumour characteristics differed by ER status, with ER– tumours
having characteristics associated with more advanced/aggressive
disease. ER− tumours had higher grade, were larger and more
likely to have positive lymph node status. The patterns of other
molecular markers also differed by ER status, with ER– tumours
more likely to be PR− and HER2+ than ER+ tumours. In contrast,
ER+ tumours were more likely to be PR+ and HER2− than ER−
tumours.
The combinations of ER/HER2 status after imputing for missing
ER and HER2 status are shown in Fig. 1a. Most tumours were ER+/
HER2−, with ER−/HER2+ tumours being the least common
combination. ER−/HER2− tumours, the most aggressive subtype,
were the second most common at 11%. Cross-sectional age-
specific curves for the ER/HER2 combinations (Fig. 1b) show
incidence of all subtypes increasing rapidly with age, until the
approximate age of menopause, age 50 years; thereafter, the
increase continued more gradually up to 70 years for ER+/HER2−
tumours, but there was no further increase for ER− tumours or
ER+/HER2+ tumours.
Age-standardised incidence rates with EAPCs from joinpoint regres-
sion. Age-standardised incidence of ER+ tumours increased
from 98 per 100,000 women in 1997 to 113 per 100,000 women
in 2016 (Table 2, Supplementary Fig. 2), with an average annual
percentage change (AAPC) of 0.4% (95% CI: −0.1 to 1%).
Incidence was higher for ER+/HER2− tumours than for the rest
of the subtypes, similar to that of ER+ tumours, with increases
observed up to 2011. Estimates from the join-point analysis
(Table 2) show that the increase in incidence of ER+ tumours was
Table 1. Descriptive characteristics by ER status for all women with an invasive breast cancer diagnosed between 1997 and 2016 in Scotland.
Characteristics ER− ER+ ER unknown
n % n % n %
11,726 [16] 55,144 [76] 5347 [8]
Age at diagnosis
<50 years 3196 (27) 10,550 (19) 695 (13)
50–69 years 5668 (48) 28,441 (52) 1580 (30)
70 years or older 2862 (24) 16,153 (29) 3072 (57)
Grade
I—well differentiated 195 (2) 8288 (15) 232 (4)
II—moderately differentiated 1714 (15) 25,734 (47) 602 (11)
III—-poorly differentiated 8308 (71) 14,586 (26) 642 (12)
Unknown 1509 (13) 6536 (12) 3871 (72)
Nodal status
Uninvolved/negative 6194 (53) 29,400 (53) 869 (16)
Involved/positive 4110 (35) 17,369 (31) 415 (8)
Unknown 1422 (12) 8375 (15) 4063 (76)
Tumour size
Less than 10mm 1017 (9) 6470 (12) 202 (4)
10–20mm 3428 (29) 20,449 (37) 478 (9)
More than 20mm 4960 (42) 18,168 (33) 512 (10)
Unknown 2321 (20) 10,057 (18) 4155 (78)
PR statusa
Negative 3803 (79) 3036 (12) <10 (<1)
Positive 226 (5) 15,869 (62) <10 (<1)
Unknown 764 (16) 6489 (26) 901 (99)
HER2 statusa
Negative 2761 (66) 18,709 (84) 36 (5)
Positive 1210 (29) 2553 (11) 10 (1)
Unknown 184 (4) 1129 (5) 725 (94)
Brackets [] indicate row percentages and parentheses () indicate column percentages for that category.
aDenotes markers that were recorded from 2009 to 2016, and the number of cases for those years= 31,099. Differences by known ER status for all
characteristics were significantly different with χ2 p < 0.001.
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reasonably constant (1.2% increase annually, 95% CI: 0.8–1.5%)
from 1997 till around 2012, after which incidence decreased by
~2.2% annually (95% CI: −4.7 to 0.4%). By contrast, ER− tumour
incidence decreased over the study period by approximately
2.5% per year (95% CI: −3.9 to –1.1%), but showed a slow rate of
decline of 0.7%/year (95% CI: −1.5, 0.0) from 2000 to 2016. ER−/
HER2− tumour incidence increased by 3.2% (95% CI: 0.3–6.1%)
from 2011 to 2016 (Supplemental Table 1 Supplementary Fig. 3),
although the latter finding was based on relatively small
numbers.
Women 50–69 years of age had the highest increases in ER+
incidence at a similar period as noted overall (Table 2, Fig. 2a),
followed by women aged 20–49 years where ER+ tumour
incidence increased by 1.1% annually. For women of 70 years or
older rates were stable. The decreases observed in ER− tumours
were consistent across the three age groups (Fig. 2b). Differences
in time trends in incidence rates were also observed between ER
+ and ER− tumours, depending on whether the tumour was
screen-detected or not. Among women aged 50–69 years with
available ER and screening data, 53% of all ER+ tumours were
screen-detected compared with 30% of ER− tumours. Further,
among women aged 50–69 years with ER+ tumours, the
incidence of non-screen-detected tumours was higher in earlier
period years of diagnosis (1997–2003) than for screen-detected
tumours. ER+ screen-detected tumours mimicked the incidence
pattern observed for all ER+ tumours, with consistent increases
in incidence until 2011, whereas non-screen-detected ER+
tumours remained constant (Fig. 2c). In women aged 50–69
years, the incidence of ER− tumours that were not screen-
detected declined over time, whereas screen-detected ER−
tumour incidence remained constant (Fig. 2d).
Age–period–cohort models. The results from APC models were
consistent with those observed from joinpoint regression, with net
drifts suggesting increases in the overall incidence of ER+
tumours by 0.8% per year (95% CI: 0.6–1.0%/year) from 1997 to
2016, and ER− tumour incidence decreasing by −1.4% (95% CI:
−1.8 to −1.1%/year). After adjusting for period and cohort effects,
local drifts showed that the highest increase in incidence of ER+
tumours was observed in women around 70 years of age (2% per
year, 95% CI: 1.6–2.4%) (Supplementary Fig. 4a). The greatest drop
in incidence of ER− tumours was observed in women of screening
age 50–69 years (Supplementary Fig. 4b).
Compared with the women born in 1949, ER+ tumour
incidence was higher among more recent birth cohorts. In
contrast, ER− incidence was lower for more recent birth cohorts
compared with the cohort born in 1949. CRRs compared with
women born in 1949 ranged from 0.7 for women born in 1913 to
1.8 for women born in 1985 for ER+ tumours, and from 1.5 for
women born in 1913 to 0.5 for women born in 1985 for ER−
tumours (Fig. 3). The combination test for ER+ tumours revealed
cohort effects beyond the log-linear trend shown by the net drift
(p value < 0.0001), but the test for ER– tumours failed to reach
significance (p value= 0.14).
DISCUSSION
This study demonstrates that, in Scotland, temporal trends of
breast cancer incidence were distinct by molecular subtypes,
with increases for ER+ and decreases for ER− tumours between
1997 and 2016. With respect to ER+ tumours, their incidence
increased for all ages for the study period, but particularly
among women of screening ages 50–69 years, with the largest
increases occurring from around 1997 to 2011 followed by
modest declines. In contrast, the incidence of ER− cancers
decreased among all ages till the early 2000s. Finally, we noted
cohort effects such that, in comparison with women born
around 1950, women of older generations (those born in the
1910s–1940s) had a lower risk of ER+ tumours, whereas there
was no significant evidence for cohort effects for ER− tumours.
Further analysis of the incidence trends by subtype (as defined
by ER/HER2 combinations) generally showed similar results to
those observed by ER status only. ER+/
HER2− (surrogate for luminal A) tumours followed the same
pattern as all ER+ tumours. However, our findings suggest a
significant increase in the rarer and more aggressive ER−/HER2
− breast cancers among women 20–49 years of age, similar to
recent increases noted in the United States that need careful
future monitoring.36 Our data affirm that future incidence and
survival reporting should be monitored by molecular subtypes
to inform clinical planning and cancer control programmes.
Consistent with reports from the United States, Denmark and
Ireland,7–9 our data show for the first time in a UK national cancer
registry, contrasting temporal trends of breast cancer incidence by
ER status, and suggest the presence of aetiologic heterogeneity
with distinct patterns by period, age at diagnosis and birth cohort.
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Previous studies have shown estimated annual increases in the
age-standardised rate of breast cancer from early 1990s to 2010
for ER+ ranging from 0.1 to 3% and declines for ER− ranging from
−1.9 to −3.4%.7–9 The Scottish Cancer Registry’s detailed tumour
hormone receptor data have been used to describe trends in
incidence patterns of breast cancer. Specifically, it was previously
reported that there were declines in ER+ tumours among women
50–64 years of age that were statistically significant by 2005.12
These findings were attributed to reduction in menopausal
hormone (MH) use (also known as hormone-replacement therapy),
which had been shown to be associated with increased risk of
breast cancer. Unlike the previous analysis, we excluded women
with a previous malignancy, imputed missing ER status and used
individuals rather than tumours as the numerator for incidence
rates, but the findings were similar for comparable years,
confirming that MH resulted in more women diagnosed with
breast cancer. The declines in breast cancer incidence coincident
with decreased MH use observed in Scottish data have also been
shown in the United States,37 Sweden, Norway38 and France.39 We
observed consistent increases over time for ER+ tumour incidence
beyond 2002, after which MH use declined. Based on recent
reports on the association of MH use and breast cancer risk, MH
has been estimated to contribute to 1 in 20 breast cancers
diagnosed worldwide since 1990.40 In more recent years, when
MH use has declined, MH has been estimated to have an
approximate 5-year lag time to breast cancer incidence, and
contribute to 2.3% of breast cancers in Scotland in recent years.
Despite reductions in MH use from 2005 to 2011, the incidence of
breast cancer continued to increase. In addition to the long-term
effects of previous MH use, other factors, such as screening
efficiency and obesity, are also likely to contribute to time trends
in breast cancer incidence.
Mammographic screening is likely to be an important contribut-
ing factor to the increased incidence of ER+ tumours we observed
from 1997 to 2011. In Scotland, the breast screening programme
was established in 1988 with full national coverage attained in
1991.41 Scotland’s breast screening programme was introduced
earlier than in other countries that have evaluated breast cancer
incidence trends by ER status (i.e. 2000 in Ireland and 2010 in
Denmark; in the United States, although there are no national
screening programmes, in the Kaiser Permanente Health Manage-
ment Organization, uptake of screening to 75% of eligible women
was seen starting in 1993)37. From 1994 to 2003, women 50–64
years of age in Scotland were invited for screening, with extension in
2003 to include women aged 65–70 years. Over the course of the
entire study period in Scotland, the mammographic screening
programme had around 75% uptake. Our data showing that ER+
tumours are more likely to be screen-detected than ER− tumours
(53% vs. 30%), and our APC model results showing incidence of ER+
tumours greatest for those of screening ages between 65 and 72
years, suggest that some of the increases observed in ER+ tumours
are likely to be due to detection of prevalent disease in these older
women. A similar pattern was also observed in the previous report.12
Our analysis among women of screening age showed that the trend
for screen-detected ER+ breast cancers is similar to that of the
overall ER+ breast cancer incidence seen in this age group, strongly
suggesting that mammographic screening is better at detection of
ER+ than ER− breast cancers. Detecting ER− breast cancers has
remained a challenge—they tend to present at younger ages, as
larger tumours, and have fewer targeted treatments unlike ER+
breast cancers.42 The natural history of breast cancer suggests a
complicated aetiology when evaluating screen-detected tumours.43
Our data suggest that ER+ screen-detected tumours have been
significantly increasing over the time period of our study although,
in more recent years, the incidence has stabilised or perhaps
declined slightly, which we intend to continue monitoring.
Yen and colleagues aimed to determine risk factors and
molecular tumour markers that might be associated with screen-T
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detected tumours using data on 1924 screen-detected and 1001
interval-detected cancer cases diagnosed in Sweden.44 They
found that higher BMI, older age at first birth, higher breast
density (the radiologic appearance of the breast) and family
history of breast cancer were significant positive contributors to
tumours that are diagnosed through mammography screening.
These data are consistent with increasing obesity and advancing
ages at first birth in the population contributing towards likely
increasing risk and therefore incidence of ER+ tumours.
Furthermore, specific molecular subtypes, such as ER− breast
cancers and the subset of ER− basal-like tumours, were more
likely to be interval cancers. Predictive modelling of breast
cancer has been proposed as a potential tool for personalised
medicine and risk-stratified screening,45–47 and future efforts
might be used within screening programmes to improve the
detection of more aggressive ER− breast cancers, particularly
amongst those at higher risk of developing such cancers. With
increased technologic advances in imaging modalities, it will be
important to assess how these impact screen-detected tumours,
and whether they can also improve detection for more
aggressive ER-negative tumours that are more likely to be
diagnosed outside of most screening programmes’ age ranges.
With increasing emphasis on efficiency in maximising limited
resources, modelling studies on stratified screening using UK
data suggest that such approaches could improve the cost-
effectiveness of the screening programme, reduce overdiagno-
sis and maintain the benefits of screening.48
The strengths of our study are the high quality of the
longitudinal data collected within the Scottish cancer registry,
the first one in the United Kingdom that routinely started
recording molecular marker data (ER status from 1997 and PR
and HER2 status from 2009). Marker data can be used to monitor
and describe incidence trends in the future and for other types of
cancer that display heterogeneity. Further, monitoring breast
cancer incidence by molecular subtypes can help the NHS allocate
resources for treatment and prevention, and lead to the
identification of high-risk groups of women for which to
implement future prevention programmes and treatments.
A potential limitation of our study is imputation of ER status for
8% of the population and the assumptions used, which were that
ER/HER2 data have the same chance of being missing among each
cohort of patients by year and age at diagnosis. For this
assumption to be wrong, there would have to be a confounder
associated with ER status that would influence whether ER status
was tested and recorded. This scenario seems unlikely in
Scotland’s health service where guidelines are used to inform
investigation and treatment. Missingness is more likely to reflect
administrative omissions, and geographic uptake in reporting ER
status. This assumption has been used in US, Denmark and Irish
data.7–9 Performing multiple imputation using additional
individual-level covariates would be more important when
describing survival. An extended imputation model for individuals
that incorporated the American Joint Committee on Cancer TNM
stage49 and tumour grade in addition to age and year of diagnosis
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found that the overall imputed counts were very similar to those
obtained using the simpler model that contained just age and
year of diagnosis.15 Therefore, redistributing the relatively small
percentage of missing receptor status in cases within each single
year of age at diagnosis and calendar year of diagnosis according
to the distribution observed for that specific cohort of patients is
appropriate for estimating incidence trends.
Another limitation of our study is the absence of individual-level
risk factor data, including participation in breast screening
programmes in prior years to define interval breast cancers and
stage data. However, in future studies, it should be possible to
identify some key factors using linked data including detailed
cohort data. The United Kingdom is renowned for its high-quality,
longitudinal data and the ability to perform linkage studies using a
unique identifier. Hence, we envision future analysis using the
cancer registry linked to other datasets, including community
prescription drug records, mammography imaging, maternity and
hospital records to provide more detailed information on the role
and patterns of key risk factors in breast cancer incidence trends.
Another limitation of the study is the lack of mRNA expression
assays for the classification of the molecular subtypes of breast
cancer. In our study, markers measured by IHC are used as
surrogates for the molecular subtypes, which are reasonably good
proxies, but mRNA profiling data would be considered a gold
standard for intrinsic-subtype classification.13
In conclusion, incidence trends of breast cancer in Scotland
differ by ER status, and are consistent with trends observed in
other countries. It will be important to monitor whether ER+
tumour incidence stabilises or reduces over time. Additional data
are needed to establish whether incidence of HER2+ tumours,
which are ER−, remains low since their treatment involves
monoclonal antibodies, such as trastuzumab and pertuzumab,13,50
which are amongst the more expensive breast cancer treatments
used by the NHS. Further research should be focused on
monitoring incidence trends by subtype because of the marked
risk, detection and treatment differences for breast cancer
subtypes.
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